FDA approves the launch of Ai Jian glaucoma gel stent

Alcon has been actively pursuing treatments for eye diseases that have not been effectively treated. The company has spent hundreds of millions of dollars on the purchase of glaucoma equipment manufacturers in the past 18 months. Now, the company's portfolio of gel stents and syringes has paid off: the device was approved by the FDA for the treatment of refractory glaucoma on Tuesday.

In September 2015, Ai Erjian acquired AqueSys for US$300 million. The Xen glaucoma treatment system under AqueSys is a new type of surgical treatment for patients with unsatisfactory previous surgery and medical treatment. The Xen45 gel scaffold is a soft shunt made of collagen-derived gelatin that approximates the width of the hair. It can be implanted into the patient's eye through a corneal incision with a pre-installed syringe.

Glaucoma is a disease that affects the optic nerve and can cause vision loss or even blindness in patients. It is usually caused by abnormally high pressure in the eye. The Xen45 implant relieves this pressure by draining aqueous humor from the anterior chamber (between the cornea and the iris) into the area below the conjunctiva. Intraocular pressure (IOP) symptoms in glaucoma patients are currently mainly relieved with eye drops, but these treatments are more cumbersome and patient compliance is lower.

FDA approves the launch of Ai Jian glaucoma gel stent

Dr. Robert Weinreb, Director of Ophthalmology and Professor of Ophthalmology at the University of California, San Diego, said: "XEN provides a new treatment option for surgical treatment of patients with refractory glaucoma. Using Xen implants for 12 months, eye drops are more than they are. Significantly reduced before implantation."

Squid Flower

Squid Flower,Frozen Calamar Flower,Frozen Octopus Flower,Frozen Pineapple Cut Squid Flower

Zhoushan Haiwang Seafood Co., Ltd. , https://www.haiwangseafoods.com